바이오테크 보도자료
-
- Advanced Clinical Continues Global Expansion Into Europe With New Office in Switzerland
- Advanced Clinical, a clinical development and strategic resourcing organization, is pleased to announce its continued expansion into Europe with the opening of a new office in Zug, Switzerland. “We have chos...
- 2022년 04월 15일
-
- Demand For Single Vinyl Siding Across Globe Is Expected To Spur Over The Forecast Owing To Boom In Construction Industry: Fact.MR
- According to the Latest Analysis By Fact.MR, the global vinyl siding market is estimated at USD 6.7 Billion in 2022 and is forecast to surpass USD 10.3 Billion by 2032, growing at a CAGR of 4.4% from 2022 to...
- 2022년 04월 15일
-
- Liquid Filled Temperature and Pressure Switches Industry Is Set to Reach Valuation Amounting to Around USD 4 Bn By 2030: Fact.MR
- According to Fact.MR, the global temperature and pressure switches demand is projected to reach a valuation amounting to around US$ 4 Bn by 2030, expanding at a steady CAGR during the 2020-2030 assessment pe...
- 2022년 04월 13일
-
- Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to
- Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO® (lanadelumab) in patients 2 to <12 years of age...
- 2022년 04월 13일
-
- DentalMonitoring, the Industry-leader in AI-powered Dental Software, Is Creating a New Business Unit, the DM Lab, as The Company Targets Continued Growth and Expansion
- The purpose of the DM Lab will be to explore, test and validate business opportunities across the broad dental market, as DentalMonitoring expands its technological leadership as well as its geographical pre...
- 2022년 04월 12일
-
- The GXP Engaged Auditing Services Group of Companies Announces the Opening of Its UK Subsidiary, GXP Engaged Auditing Services UK Ltd.
- As well as extending the reach of our comprehensive contract quality management and auditing services for our clients in the pharmaceutical, biotechnology, medical devices, nutrition and healthcare industrie...
- 2022년 04월 12일
-
- Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022
- Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-gen...
- 2022년 04월 11일
-
- Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie
- Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has today announced the resolution of...
- 2022년 04월 07일
-
- Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
- Takeda (TSE:4502/NYSE:TAK) and the New York Academy of Sciences today announced the winners of the fourth Innovators in Science Award for their excellence in, and commitment to, innovative science that has s...
- 2022년 04월 06일
-
- Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests
- Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio inclu...
- 2022년 04월 06일
-
- Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
- In 2021, Boehringer Ingelheim again stepped up its annual investments in R&D to a new high in its 137-year history. The company spent 4.1 billion EUR on R&D (2020: 3.7 billion EUR), up 11.7%. R&D investments...
- 2022년 04월 05일
-
- DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve long-term potassium ...
- 2022년 04월 04일
-
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
- Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors will propose two new candidates for independent external directors at the 146th Ordinary Meeting of Shareholders on June 29, 2022. The...
- 2022년 04월 04일
전시회
